Febri Ardiana and Suciati and Gunawan Indrayanto (2015) Valsartan (Profiles of Drugs Substances, Excipients and Related Methodology). In: Profiles of Drugs Substances, Excipients and Related Methodology. Elsevier Academic Press, San Diego, pp. 431-493. ISBN 978-0-12-803300-5

	Text (FULLTEXT) C-04 Artikel.pdf Download (16MB)
	Text (PEER REVIEW) C-04 Reviewer.pdf Download (1MB)
	Text (SIMILARITY) C-04 Result.pdf Download (9MB)

Abstract

Valsartan is an antihypertensive drug which selectively inhibits angiotensin receptor type II. This tetrazole derivative was first developed by Novartis and marketed under brand name Diovan® . This compound is orally active and is rapidly absorbed after oral doses, having a bioavailability of approximately 23% . Valsartan appears as a white or almost white hygroscopic powder. This compound must be kept in an air-tight container and should be protected from light and heat. It is available in film-coated tablets containing valsartan 40, 80, 160, or 320 mg, and capsules with dosage of 80 or 160 mg. Tablet combinations of valsartan with hydrochlorothiazide or amlodipine are also available

Item Type:	Book Section
Uncontrolled Keywords:	Valsartan;Assay;Bioanalysis;Chromatography;Impurities;Polymorphs;Related compound;Spectroscopy
Subjects:	R Medicine R Medicine > RS Pharmacy and materia medica
Divisions:	05. Fakultas Farmasi
Creators:	Creators NIM Febri Ardiana NIM050012249 Suciati NIDN0004117905 Gunawan Indrayanto UNSPECIFIED
Depositing User:	Mr M. Fuad Sofyan
Date Deposited:	24 Jan 2020 02:46
Last Modified:	05 Feb 2020 04:16
URI:	http://repository.unair.ac.id/id/eprint/93642
Sosial Share:

Actions (login required)

View Item